Survival in Budd-Chiari syndrome patients. (A) Overall survival according to JAK2V617F. (B) Overall survival according to the existence of underlying MPD. (C) Event-free survival according to presence of JAK2V617F. (D) Event-free survival according to the existence of underlying MPD.